Administering Shingles Vaccine Prior to the Initiation of Biologics Therapy: A Systematic Review
Keywords:
Shingles, Herpes zoster, Varicella-zoster virus, Vaccine prophylaxis, BiologicsAbstract
Background: Shingles, also known as herpes zoster, is a viral infection caused by the varicella-zoster virus. The classic feature is a painful dermatomal rash. Although the disease is often self-limiting, complications such as postherpetic neuralgia can cause long-lasting morbidity. Patients who are immunosuppressed are more susceptible to developing shingles. The purpose of this paper is to systematically review the evidence for prophylactic use of the shingles vaccine prior to initiating biological therapy.
Objectives: To evaluate the evidence for shingles vaccine prophylaxis prior to initiating biologics therapy.
Methods: We performed a comprehensive Boolean search of PubMed and EMBASE from January 2000 to October 2019 for the following terms: prophylaxis, prior, shingles vaccine, varicella-zoster, infliximab, biological therapy, and guidelines. Eligible studies met the following criteria: published in English since 2000, used any shingles vaccine type and dose; and involved both vaccine monotherapy and autoimmune disease biological therapy. Randomised controlled trials, meta-analyses, and systematic reviews were included. Duplicate studies were excluded, as well as non-English papers.
Results: 32 studies met the search criteria, of which 8 were selected for the literature review. All studies had generally differing conclusions as to whether shingles vaccination in autoimmune patients undertaking biologic therapy was safe and effective.
Conclusions: Patients with autoimmune diseases should be considered for the herpes zoster vaccine prior to initiating biological therapy. Our findings support the use of the live attenuated vaccine, Zostavax, or the non-live vaccine, Shingrix. However, further research is required to evaluate specific autoimmune conditions and specific biological agents with a view to the formulation of national clinical guidelines on the use of the herpes zoster vaccine in the immunocompromised.
References
Health Service Executive. Health A-Z [Internet]. Hse.ie. [cited 10 January 2022]. Available from: https://www.hse.ie/eng/health/az/s/shingles/
Marra F, Lo E, Kalashnikov V, Richardson K. Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/ or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2016;3(4).
Rosman Z, Shoenfeld Y, Zandman-Goddard G. Biologic therapy for autoimmune diseases: an update. BMC Medicine. 2013;11(1).
Chen Y, Gong FY, Li ZJ, et al. A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis. Sci Rep. 2017;7(1):6779.
Yun H, Yang S, Chen L, et al. Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination. Arthritis Rheumatol. 2016;68:2328-2337. Doi:10.1002/art.39670.
Her M, Kavanaugh A. Alterations in immune function with biologic therapies for autoimmune disease. J Allergy Clin Immunol. 2016;137(1):19-27.
Oxman, M., Levin, M., Johnson, G., et al. A Vaccine to Prevent Herpes Zoster and Post herpetic Neuralgia in Older Adults. NEJM. 2005; 352:2271-2284.
Good C, Parekh N, Hernandez I. Avoiding rash decisions about zoster vaccination: insights from cost-effectiveness evidence. BMC Medicine. 2018;16(1).
Curtis J, Singh J. Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care. Clin Ther. 2011;33(6):679-707.
Kopylov U, Levin A, Mendelson E et al. Prior varicella zoster
virus exposure in IBD patients treated by anti-TNFs and other immunomodulators: implications for serological testing and vaccination guidelines. Aliment Pharmacol Ther. 2012;36(2):145-150.
Zhang J, Xie F, Delzell E, Chen L, Winthrop K, Lewis J et al. Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases. JAMA. 2012;308(1):43-49.
Eberhardson M, Hall S, Papp K, Sterling T, Stek J, Pang L et al. Safety
and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults with Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Clin Infect Dis. 2017;65(7):1174-1182.
Cheetham T, Marcy S, Tseng H, Sy L, Liu I, Bixler F et al. Risk of
Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clin Proc. 2015;90(7):865-873.
Singh R. Identifying ‘at-risk’ inflammatory bowel disease patients who may be targeted with a new adjuvant herpes zoster subunit vaccine. J Crohns Colitis. 2016;10(1):S365-S366.
Marra F, Lo E, Kalashnikov V, Richardson K. Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/ or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis. Open Forum Infect Dis. 2016;3(4):205.
Furer V, Rondaan C, Heijstek M, Agmon-Levin N, van Assen S, Bijl M et
al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019;79(1):39-52.
Winthrop K, Wouters A, Choy E, Soma K, Hodge J, Nduaka C et al. The Safety and Immunogenicity of Live Zoster Vaccination in Patients with Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial. Arthritis Rheumatol. 2017;69(10):1969-1977.
Rose N. Prediction and Prevention of Autoimmune Disease in the 21st Century: A Review and Preview. Am J Epidemiol. 2016;183(5):403-406.
Papadopoulou D, Sipsas N. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol. 2013;34(2):151-163.
Yun H, Xie F, Baddley J et al. Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases. J Rheumatol. 2017;44(7):1083-1087.
Gershon, A. Vaccination to prevent zoster in the elderly. Epidemiol Infect. 2007;135(6):883-886.
Dooling, K. L., Guo, A., Patel, M., Lee, G. M., Moore, K., Belongia, E. A., & Harpaz, R. (2018). Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines. Am J Transplant, 18(3):756–762.
Furer V, Rondaan C, Heijstek M, Agmon-Levin N, van Assen S, Bijl M et
al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019;79(1):39-52.
UpToDate. Immunizations in autoimmune inflammatory rheumatic disease in adults [Internet]. Uptodate.com; 2019 [cited 10 January 2022]. Available from: https://www.uptodate.com/contents/immunizations-in- autoimmune-inflammatory-rheumatic-disease-in-adults
Public Health England. Immunisation against infectious diseases. [Internet]. Public Health England; 2013 [cited 3 November 2019]. Available from: https://www.gov.uk/government/collections/ immunisation-against-infectious-disease-the-green-book#the-green- book
Baxter R, Bartlett J, Fireman B et al. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol. 2017;187(1):161-169.
Alexander K, Tong P, Macartney K et al. Live zoster vaccination in
an immunocompromised patient leading to death secondary to disseminated varicella zoster virus infection. Vaccine. 2018;36(27):3890- 3893.
Pellissier J, Brisson M, Levin M. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Vaccine. 2007;25(49):8326-8337.
Health Information and Quality Authority. Guidelines for the Economic Evaluation of Health Technologies in Ireland [Internet]. Hiqa.ie; 2019 [cited 10 January 2022]. Available from: https://www.hiqa.ie/sites/ default/files/2019-07/HTA-Economic-Guidelines-2019.pdf
ClinicalTrials.gov. Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) - Full Text View - ClinicalTrials.gov [Internet]. Clinicaltrials.gov; 2019 [cited 10 January 2022]. Available from: https://clinicaltrials.gov/ct2/show/NCT02538341
Downloads
Published
How to Cite
License
Copyright (c) 2024 Alicia Ryan, Alex Soo, Niall O’Rourke, Ayub Nasrudin, Dan Khan, Fiona Lafferty, James Kelly, Nicola Byrne, Serhiy Semenov
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
